GB201716871D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201716871D0
GB201716871D0 GBGB1716871.7A GB201716871A GB201716871D0 GB 201716871 D0 GB201716871 D0 GB 201716871D0 GB 201716871 A GB201716871 A GB 201716871A GB 201716871 D0 GB201716871 D0 GB 201716871D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1716871.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Priority to GBGB1716871.7A priority Critical patent/GB201716871D0/en
Publication of GB201716871D0 publication Critical patent/GB201716871D0/en
Priority to PCT/GB2018/052934 priority patent/WO2019073251A1/en
Priority to EP18792450.1A priority patent/EP3694857A1/en
Priority to CA3076566A priority patent/CA3076566A1/en
Priority to CN201880065806.5A priority patent/CN111212836B/zh
Priority to US16/755,739 priority patent/US11325915B2/en
Priority to JP2020520592A priority patent/JP7385561B2/ja
Priority to IL273727A priority patent/IL273727B2/en
Priority to US17/712,541 priority patent/US12060360B2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1716871.7A 2017-10-13 2017-10-13 Compounds Ceased GB201716871D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1716871.7A GB201716871D0 (en) 2017-10-13 2017-10-13 Compounds
PCT/GB2018/052934 WO2019073251A1 (en) 2017-10-13 2018-10-12 INHIBITORS OF LYSYL OXIDASE
EP18792450.1A EP3694857A1 (en) 2017-10-13 2018-10-12 Lysyl oxidase inhibitors
CA3076566A CA3076566A1 (en) 2017-10-13 2018-10-12 Lysyl oxidase inhibitors
CN201880065806.5A CN111212836B (zh) 2017-10-13 2018-10-12 赖氨酰氧化酶抑制剂
US16/755,739 US11325915B2 (en) 2017-10-13 2018-10-12 Lysyl oxidase inhibitors
JP2020520592A JP7385561B2 (ja) 2017-10-13 2018-10-12 化合物
IL273727A IL273727B2 (en) 2017-10-13 2020-03-31 Lysyl oxidase inhibitors
US17/712,541 US12060360B2 (en) 2017-10-13 2022-04-04 Lysyl oxidase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1716871.7A GB201716871D0 (en) 2017-10-13 2017-10-13 Compounds

Publications (1)

Publication Number Publication Date
GB201716871D0 true GB201716871D0 (en) 2017-11-29

Family

ID=60419229

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1716871.7A Ceased GB201716871D0 (en) 2017-10-13 2017-10-13 Compounds

Country Status (8)

Country Link
US (2) US11325915B2 (https=)
EP (1) EP3694857A1 (https=)
JP (1) JP7385561B2 (https=)
CN (1) CN111212836B (https=)
CA (1) CA3076566A1 (https=)
GB (1) GB201716871D0 (https=)
IL (1) IL273727B2 (https=)
WO (1) WO2019073251A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN112533897B (zh) 2018-08-03 2023-07-14 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺砜衍生抑制剂及其用途
GB201818750D0 (en) * 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
AU2020317374A1 (en) * 2019-07-25 2022-02-03 Pharmaxis Ltd. Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US12578335B2 (en) 2020-02-05 2026-03-17 Syntara Limited Bioprobes for lysyl oxidases and uses thereof
US20230310445A1 (en) * 2020-04-21 2023-10-05 Anovia Biosciences, Inc. Lox enzyme inhibiting methods and compositions
US12233056B2 (en) 2022-04-06 2025-02-25 Syntara Limited Lysyl oxidase inhibitors for treating myeloid malignancies
CN116763899B (zh) * 2023-07-17 2026-02-24 大连医科大学附属第一医院 Htra1抑制剂在制备治疗胰腺炎-癌转化的药物中的应用
CN119732928B (zh) * 2024-12-26 2026-04-07 国家纳米科学中心 一种抑制胶原纤维形成的药物分子及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992546A (en) 1987-07-31 1991-02-12 Warner-Lambert Company Process for preparing 6,8-diazabicyclo[3.2.2]nonane derivatives
DE4402933A1 (de) 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
CA2657623A1 (en) * 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
BRPI0821676A2 (pt) 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2011119345A2 (en) 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2014348518B2 (en) * 2013-11-14 2019-01-03 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9994570B2 (en) 2014-11-26 2018-06-12 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
EP3267996B1 (en) * 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
EP3317258A4 (en) * 2015-07-01 2019-06-26 Pharmakea, Inc. LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF
ES2880766T3 (es) 2016-02-09 2021-11-25 Pharmakea Inc Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
JP6849197B2 (ja) 2016-02-12 2021-03-24 ファーマクシス リミテッド リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
US20210009551A1 (en) 2016-06-02 2021-01-14 The Regents Of The University Of California Compounds and methods for treating fibrosis or cancer
WO2018048928A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Chemical probes of lysyl oxidase-like 2 and uses thereof
WO2018048930A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
KR102587178B1 (ko) 2016-09-07 2023-10-06 파마케아, 인크. 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법
US20200069648A1 (en) 2017-03-02 2020-03-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds

Also Published As

Publication number Publication date
CN111212836B (zh) 2023-12-15
US20200331922A1 (en) 2020-10-22
EP3694857A1 (en) 2020-08-19
US12060360B2 (en) 2024-08-13
US11325915B2 (en) 2022-05-10
CA3076566A1 (en) 2019-04-18
US20220289757A1 (en) 2022-09-15
WO2019073251A1 (en) 2019-04-18
JP2020536924A (ja) 2020-12-17
IL273727B2 (en) 2023-06-01
CN111212836A (zh) 2020-05-29
JP7385561B2 (ja) 2023-11-22
IL273727A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201716871D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201717051D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201720064D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201721330D0 (en) Compounds
GB201721326D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201719261D0 (en) Compounds
GB201717718D0 (en) Compounds
GB201717050D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)